[{"indications": "Indications\u00a0prophylaxis of organ rejection in kidney allograft recipients (initially\r\nin combination with ciclosporin and corticosteroid, then with corticosteroid\r\nonly); see also under Dose", "name": "SIROLIMUS", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "8 Malignant disease and immunosuppression", "8.2 Drugs affecting the immune response", "8.2.2 Corticosteroids and other immunosuppressants", "SIROLIMUS"], "cautions": "Cautions\u00a0monitor kidney function when given with\r\nciclosporin; monitor whole blood-sirolimus\r\ntrough concentration (Afro-Caribbean patients may require higher doses); hyperlipidaemia (monitor lipids); monitor urine proteins; increased susceptibility\r\nto infection (especially urinary-tract infection); increased susceptibility to lymphoma and other malignancies, particularly\r\nof the skin (limit exposure to UV light); interactions: Appendix 1 (sirolimus)", "side-effects": "Side-effects\u00a0abdominal pain, constipation, nausea, diarrhoea,\r\nascites, stomatitis; oedema, tachycardia, hypertension, hypercholesterolaemia,\r\nhypertriglyceridaemia, venous thromboembolism; pleural effusion, pneumonitis;\r\nheadache; pyrexia; proteinuria, haemolytic uraemic syndrome; anaemia,\r\nthrombocytopenia, thrombotic thrombocytopenic purpura, leucopenia,\r\nneutropenia, hypokalaemia, hypophosphataemia, hyperglycaemia, lymphocele;\r\narthralgia, osteonecrosis; epistaxis; acne, rash, impaired healing; less commonly pancreatitis, pulmonary embolism, pulmonary\r\nhaemorrhage, pericardial effusion, nephrotic syndrome, pancytopenia; rarely interstitial lung disease, alveolar proteinosis,\r\nhepatic necrosis, lymphoedema, and hypersensitivity reactions including\r\nanaphylactic reactions, angioedema, exfoliative dermatitis, and hypersensitivity\r\nvasculitis; focal segmental glomerulosclerosis and reversible impairment\r\nof male fertility also reported", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/106035.htm", "doses": ["Initially 6\u00a0mg, after surgery (once wound has healed),\r\nthen 2\u00a0mg once daily (dose adjusted according to whole blood-sirolimus\r\ntrough concentration) in combination with ciclosporin and corticosteroid\r\nfor 2\u20133 months (sirolimus given 4 hours after ciclosporin); ciclosporin\r\nshould then be withdrawn over 4\u20138 weeks (if not possible, sirolimus\r\nshould be discontinued and an alternate immunosuppressive regimen\r\nused)", "Manufacturer advises pre-dose (\u2018trough\u2019)\r\nwhole blood-sirolimus concentration (using chromatographic assay) when used with ciclosporin should be 4\u201312\u00a0micrograms/litre\r\n(local treatment protocols may differ); after withdrawal of ciclosporin\r\npre-dose whole blood-sirolimus concentration should be 12\u201320\u00a0micrograms/litre\r\n(local treatment protocols may differ); close monitoring\r\nof whole blood-sirolimus concentration required if concomitant treatment\r\nwith potent inducers or inhibitors of metabolism and after discontinuing\r\nthem, or if ciclosporin dose reduced significantly or stopped; see\r\nalso Hepatic Impairment above", "When changing between oral solution and tablets, measurement\r\nof whole blood \u2018trough\u2019 sirolimus concentration after 1\u20132 weeks is\r\nrecommended", "Sirolimus whole-blood\r\nconcentration is measured using either high performance liquid chromatography\r\n(HPLC) or immunoassay. Switching between different immunoassays or\r\nbetween an immunoassay and HPLC can lead to clinically significant\r\ndifferences in results and therefore incorrect dose adjustments. Adjustment\r\nto the target therapeutic dose range should be made with knowledge\r\nof the assay used and corresponding reference range"], "pregnancy": "Pregnancy\u00a0avoid unless essential\u2014(toxicity in animal studies); effective contraception must be used during treatment\r\nand for 12 weeks after stopping"}]